



National Institute of  
Neurological Disorders  
and Stroke

NIH Counter**ACT**  
Program

# Status Epilepticus after Benzodiazepines: Seizures and Improving Long-term Outcomes

February 28 - March 1, 2023



## Real world implementation of status epilepticus care: seizing an opportunity for improvement

**Elan L. Guterman, MD MAS**

Assistant Professor of Neurology, UCSF

Affiliate Faculty, Philip R. Lee Institute for Health Policy Studies, UCSF

# Status Epilepticus after Benzodiazepines: Seizures and Improving Long-term Outcomes




## Disclaimer

This certifies that the views expressed in this presentation are those of the author and do not reflect the official policy of NIH.

## Disclosure

This certifies that I, Elan Guterman, have no financial relationship that is relevant to the subject matter of the presentation. I have previously received fees from Marinus Pharmaceuticals, Inc and currently receive fees from JAMA Neurology and stock from REMO Health, Inc which are unrelated to the current presentation.

Status epilepticus-related-mortality is high and unchanged over time



### **Translation 1**


Developing new therapies  
for status epilepticus

### **Translation 2**

Evaluating therapies in the  
real world

### **Translation 3**

Delivering therapies in the  
real world



### Translation 1


Developing new therapies  
for status epilepticus

### Translation 2

Evaluating therapies in the  
real world

### Translation 3

Delivering therapies in the  
real world



- Outcomes and comparative effectiveness research
- Health services research

- Implementation science
- Measurement & accountability
  - Dissemination
- Health care system redesign

# Continuum of status epilepticus care



# Clinical case

4-year-old boy with no history of epilepsy is brought to the hospital by ambulance after having a generalized convulsion at home in the setting of a febrile viral illness. En route, he has a GCS of 8 and is given IV fluids and oxygen. In the ED, he has gaze deviation and dyskinetic movements of his face and you are paged to admit him to the ICU.

**What is the likelihood of status epilepticus being detected in the prehospital setting?**

# Prehospital misdiagnosis of status epilepticus

**150 adult patients** brought in by EMS and diagnosed with SE in the ED

- 26 convulsive SE
- 124 NCSE

**Calculated proportion of SE missed in prehospital setting**


- SE missed 55.3% (83/150)
- SE missed more frequently in NCSE
  - NCSE missed in 63.7% (79/124)
  - CSE missed in 15.4% (4/26)

Prehospital principal diagnosis	Overall (n=150)	
	Suspected by emergency medical service	
	n	%
<b>Suspected epileptic event</b>	67	44.7
• Status epilepticus	32	21.3
• Seizures	35	23.3
<b>Missed epileptic event (=Alternative suspected diagnosis without suspected SE)</b>	83	55.3
• Unknown neurologic event	37	24.7
• Acute ischemic stroke	35	23.3
• Intracranial hemorrhage	4	2.7
• Cardiac emergency	4	2.7
• Traumatic brain injury	3	2.0



# Evidence that prehospital status epilepticus detection impacts outcomes

	Missed NCSE (n = 79)	Correctly suspected NCSE (n = 45)	P value
<b>No recovery to baseline (among survivors)</b>	38 (of 70 survivors; 54.3%)	10 (of 39 survivors; 25.6%)	0.004
<b>In-hospital death</b>	9 (11.4%)	6 (13.3%)	0.779
<b>Death within 30 days</b>	10 (12.7%)	7 (15.6%)	0.787



# Clinical case

4-year-old boy with no history of epilepsy is brought to the hospital by ambulance after having a generalized convulsion at home in the setting of a febrile viral illness. En route, he has a GCS of 8 and is given IV fluids and oxygen. In the ED, he has gaze deviation and dyskinetic movements of his face and you are paged to admit him to the ICU.

**What is the likelihood of status epilepticus being detected in the prehospital setting? Less than 40% among those with NCSE**

# Clinical case


4-year-old boy with no history of epilepsy is brought to the hospital by ambulance after having a generalized convulsion at home in the setting of a febrile viral illness. En route, he has a GCS of 8 and is given IV fluids and oxygen. In the ED, he has gaze deviation and dyskinetic movements of his face and you are paged to admit him to the ICU.

**How and when was he treated with first-line treatment?**

# Minutes matter for status epilepticus control


	<b>IV Lorazepam</b>	<b>IM Midazolam</b>
<b>Status epilepticus treated</b>	<b>63.4%</b>	<b>73.4%</b>
<b>Time outcomes</b>		
<i>Time to medication administration</i>	4.8 minutes	1.2 minutes
<i>Time from medication administration to seizure termination</i>	1.6 minutes	3.3 minutes
<b><i>Total time to seizure termination</i></b>	<b>6.4 minutes</b>	<b>4.5 minutes</b>

# Delays in treatment for out-of-hospital RSE




**Time to first  
benzodiazepine**

20 minutes  
(IQR 8–55)



**Time to first non-  
benzodiazepine ASM**

80 minutes  
(IQR 45–165)



**Time to first infusion**

164 minutes  
(IQR 97.5–641)

# Prehospital status epilepticus treatment is not consistent with national guidelines

	All	Intramuscular	Intranasal	Intravenous	Other <sup>a</sup>
<b>Midazolam</b>					
<5mg	3289 (42.9%)	648 (8.5%)	559 (7.3%)	2061 (26.9%)	21 (0.3%)
5mg	3809 (49.7%)	1677 (21.9%)	788 (10.3%)	1331 (17.4%)	13 (0.2%)
>5 and <10mg	22 (0.3%)	6 (0.1%)	3 (0.0%)	13 (0.2%)	0 (0.0%)
10mg	541 (7.1%)	310 (4.0%)	154 (2.0%)	72 (1.0%)	5 (0.1%)
<b>Total</b>	<b>7,665</b>	<b>2,641</b>	<b>1,504</b>	<b>3,481</b>	<b>39</b>
<b>Lorazepam</b>					
<2mg	331 (26.2%)	40 (3.2%)	18 (1.4%)	268 (21.2%)	5 (0.4%)
2mg	890 (70.4%)	188 (14.9%)	47 (3.7%)	640 (50.6%)	15 (1.2%)
>2 and <4mg	2 (0.2%)	1 (0.1%)	0 (0.0%)	1 (0.1%)	0 (0.0%)
4mg	35 (2.8%)	13 (1.0%)	2 (0.2%)	18 (1.4%)	2 (0.2%)
<b>Total</b>	<b>1,264</b>	<b>245</b>	<b>69</b>	<b>928</b>	<b>22</b>
<b>Diazepam</b>					
<6mg	207 (84.5%)	18 (7.4%)	25 (10.2%)	162 (66.1%)	2 (0.8%)
≥6mg and ≤10mg	38 (15.5%)	2 (0.8%)	2 (0.8%)	29 (11.8%)	5 (2.0%)
<b>Total</b>	<b>245</b>	<b>20</b>	<b>27</b>	<b>191</b>	<b>7</b>


# Clinical case

4-year-old boy with no history of epilepsy is brought to the hospital by ambulance after having a generalized convulsion at home in the setting of a febrile viral illness. En route, he has a GCS of 8 and is given IV fluids and oxygen. In the ED, he has gaze deviation and dyskinetic movements of his face and you are paged to admit him to the ICU.


- **Delayed diagnosis**
- **Delayed treatment**
- **Underdosed medication**

# Inequitable access to high quality care

■ Black (n = 102) ■ White (n = 266)






Proportion of U.S. Hospitals with EEG Capability





# Where are we going?



# New era in early interventions for status epilepticus and other neurologic emergencies

*The* **NEW ENGLAND**  
**JOURNAL** *of* **MEDICINE**

ESTABLISHED IN 1812

FEBRUARY 16, 2012

VOL. 366 NO. 7

## Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus

Robert Silbergleit, M.D., Valerie Durkalski, Ph.D., Daniel Lowenstein, M.D., Robin Conwit, M.D., Arthur Pancioli, M.D., Yuko Palesch, Ph.D., and William Barsan, M.D., for the NETT Investigators\*

JAMA Surgery | **Original Investigation**

## Association of Statewide Implementation of the Prehospital Traumatic Brain Injury Treatment Guidelines With Patient Survival Following Traumatic Brain Injury The Excellence in Prehospital Injury Care (EPIC) Study

Daniel W. Spaite, MD; Bentley J. Bobrow, MD; Samuel M. Keim, MD, MS; Bruce Barnhart, RN, CEP; Vatsal Chikani, MPH; Joshua B. Gaither, MD; Duane Sherrill, PhD; Kurt R. Denninghoff, MD; Terry Mullins, MPH, MBA; P. David Adelson, MD; Amber D. Rice, MD, MS; Chad Viscusi, MD; Chengcheng Hu, PhD

The New England  
Journal of Medicine

Copyright © 2001 by the Massachusetts Medical Society

VOLUME 345

AUGUST 30, 2001

NUMBER 9



A COMPARISON OF LORAZEPAM, DIAZEPAM, AND PLACEBO FOR THE TREATMENT OF OUT-OF-HOSPITAL STATUS EPILEPTICUS

BRIAN K. ALLDREDGE, PHARM.D., ALAN M. GELB, M.D., S. MARSHAL ISAACS, M.D., MEGAN D. CORRY, E.M.T.-P., M.A., FAITH ALLEN, M.D., SUEKAY ULRICH, R.N., M.S., MILDRED D. GOTTWALD, PHARM.D., NELDA O'NEIL, R.N., M.S.N., JOHN M. NEUHAUS, PH.D., MARK R. SEGAL, PH.D., AND DANIEL H. LOWENSTEIN, M.D.

*The* **NEW ENGLAND**  
**JOURNAL** *of* **MEDICINE**

ESTABLISHED IN 1812

SEPTEMBER 9, 2021

VOL. 385 NO. 11

## Prospective, Multicenter, Controlled Trial of Mobile Stroke Units

J.C. Grotta, J.-M. Yamal, S.A. Parker, S.S. Rajan, N.R. Gonzales, W.J. Jones, A.W. Alexandrov, B.B. Navi, M. Nour, I. Spokoiny, J. Mackey, D. Persse, A.P. Jacob, M. Wang, N. Singh, A.V. Alexandrov, M.E. Fink, J.L. Saver, J. English, N. Barazangi, P.L. Bratina, M. Gonzalez, B.D. Schimpf, K. Ackerson, C. Sherman, M. Lerario, S. Mir, J. Im, J.Z. Willey, D. Chiu, M. Eisshofer, J. Miller, D. Ornelas, J.P. Rhudy, K.M. Brown, B.M. Villareal, M. Gausche-Hill, N. Bosson, G. Gilbert, S.Q. Collins, K. Silnes, J. Volpi, V. Misra, J. McCarthy, T. Flanagan, C.P.V. Rao, J.S. Kass, L. Griffin, N. Rangel-Gutierrez, E. Lechuga, J. Stephenson, K. Phan, Y. Sanders, E.A. Noser, and R. Bowry

# Conclusions



EMS is a critical partner in delivering high-quality status epilepticus care



Vast majority of patients do not receive evidence-based care with clear gaps in diagnosis and treatment



We need improved systems to ensure equitable access to high quality care for status epilepticus and other neurologic emergencies

# Status Epilepticus after Benzodiazepines: Seizures and Improving Long-term Outcomes



Thanks.

Elan.Guterman@ucsf.edu